Comparing SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights

A Decade of SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. Over the past decade, Alkermes plc and Arrowhead Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Alkermes plc's SG&A expenses surged by approximately 245%, peaking in 2023. This growth reflects their strategic investments in expanding operations and market reach. In contrast, Arrowhead Pharmaceuticals, Inc. experienced a more modest increase of around 272% over the same period, with a notable spike in 2022. This suggests a focused approach towards scaling their business operations. Interestingly, while Alkermes consistently outspent Arrowhead, the latter's rapid growth in recent years indicates a potential shift in competitive dynamics. As we look to the future, these trends offer valuable insights into the strategic priorities of these pharmaceutical giants.